{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T13:42:16Z","timestamp":1780148536525,"version":"3.54.0"},"reference-count":36,"publisher":"Oncology Nursing Society (ONS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2011,10,1]]},"DOI":"10.1188\/11.cjon.e83-e89","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T01:19:11Z","timestamp":1317172751000},"page":"E83-E89","source":"Crossref","is-referenced-by-count":60,"title":["Managing Stomatitis in Patients Treated With Mammalian Target of Rapamycin Inhibitors"],"prefix":"10.1188","volume":"15","author":[{"given":"Amy Potter","family":"Pilotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Beth","family":"Hohos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M. O.","family":"Polson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarsha Marie","family":"Huftalen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Treister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2011,9,27]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"M. Atkins","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"2","article-title":"NCCN Task Force Report: Prevention and management of mucositis in cancer care","volume":"6","author":"W. Bensinger","year":"2008","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: A target for cancer therapy","volume":"4","author":"M. Bjornsti","year":"2004","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.soncn.2003.10.004","article-title":"Clinical consequences of oral mucositis","volume":"20","author":"C. Brown","year":"2004","journal-title":"Seminars in Oncology Nursing"},{"key":"5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s10637-009-9257-1","article-title":"Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer","volume":"28","author":"J. Buckner","year":"2010","journal-title":"Investigational New Drugs"},{"key":"6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/bcr927","article-title":"New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists","volume":"6","author":"H. Carraway","year":"2004","journal-title":"Breast Cancer Research"},{"key":"7","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"S. Chan","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"8","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","article-title":"The type 1 insulin-like growth factor receptor pathway","volume":"14","author":"M. Chitnis","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1600-6143.2006.01678.x","article-title":"Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus","volume":"7","author":"P. Chuang","year":"2007","journal-title":"American Journal of Transplantation"},{"key":"10","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1517\/13543784.17.11.1717","article-title":"mTOR inhibitors in the treatment of cancer","volume":"17","author":"A. Fasolo","year":"2008","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"11","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"M. Hidalgo","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/sj.bjc.6603910","article-title":"Targeting HER proteins in cancer therapy and the role of the non-target HER3","volume":"97","author":"A. Hsieh","year":"2007","journal-title":"British Journal of Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"G. Hudes","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00128071-200304100-00002","article-title":"Management strategies for HIV-associated aphthous stomatitis","volume":"4","author":"A. Kerr","year":"2003","journal-title":"American Journal of Clinical Dermatology"},{"key":"15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"A. MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","article-title":"Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy","volume":"79","author":"E. Mah\u00e9","year":"2005","journal-title":"Transplantation"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Mita, M. M., Britten, C. D., Poplin, E., Tap, W. D., Carmona, A., Yonemoto, L., \u2026 Tolcher, A. W. (2008). Deforolimus trial 106\u2014A phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669) [Abstract 3509.]. <a target=\"_blank\" href='http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32547'>http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32547<\/a>","DOI":"10.1200\/jco.2008.26.15_suppl.3509"},{"key":"18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"M. Mita","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"R. Motzer","year":"2008","journal-title":"Lancet"},{"key":"20","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"R. Motzer","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"21","unstructured":"National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Retrieved from <a target=\"_blank\" href='http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm'>http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm<\/a>"},{"key":"22","unstructured":"National Institutes of Health. (2011). Ridaforolimus in treatment of sarcoma\u2014SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus). Retrieved from <a target=\"_blank\" href='http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00538239?term=00538239&rank=1'>http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00538239?term=00538239&rank=1<\/a>"},{"key":"23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1600-0714.2007.00507.x","article-title":"Subantimicrobial dose doxycycline in the treatment of recurrent oral aphthous ulceration: A pilot study","volume":"36","author":"P. Preshaw","year":"2007","journal-title":"Journal of Oral Pathology and Medicine"},{"key":"24","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"E. Raymond","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","article-title":"The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents","volume":"4","author":"K. Sankhala","year":"2009","journal-title":"Targeted Oncology"},{"issue":"1","key":"26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: A review of the evidence","volume":"59","author":"R. Saunders","year":"2001","journal-title":"Kidney International"},{"key":"27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1056\/NEJMcp054630","article-title":"Clinical practice. Aphthous ulceration","volume":"355","author":"C. Scully","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.14219\/jada.archive.2003.0134","article-title":"The diagnosis and management of recurrent aphthous stomatitis: A consensus approach","volume":"134","author":"C. Scully","year":"2003","journal-title":"Journal of the American Dental Association"},{"key":"29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bjoms.2007.07.201","article-title":"Oral mucosal disease: Recurrent aphthous stomatitis","volume":"46","author":"C. Scully","year":"2008","journal-title":"British Journal of Oral and Maxillofacial Surgery"},{"key":"30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K, and mTOR signalling controls tumour cell growth","volume":"441","author":"R. Shaw","year":"2006","journal-title":"Nature"},{"key":"31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"S. Sonis","year":"2010","journal-title":"Cancer"},{"key":"32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"J. Tabernero","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/01.TP.0000056639.74982.F9","article-title":"Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil","volume":"75","author":"T. van Gelder","year":"2003","journal-title":"Transplantation"},{"key":"34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","author":"S. Vignot","year":"2005","journal-title":"Annals of Oncology"},{"key":"35","first-page":"273","article-title":"Cutaneous effects of sirolimus in renal transplant recipients","volume":"5","author":"L. Warino","year":"2006","journal-title":"Journal of Drugs in Dermatology"},{"key":"36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-8722-2-45","article-title":"Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy","volume":"2","author":"R. Yuan","year":"2009","journal-title":"Journal of Hematology and Oncology"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/M702677028J7667M.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:48:21Z","timestamp":1763754501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/15\/5\/managing-stomatitis-patients-treated-mammalian-target-rapamycin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,27]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10,1]]}},"alternative-id":["M702677028J7667M"],"URL":"https:\/\/doi.org\/10.1188\/11.cjon.e83-e89","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,27]]}}}